First Quadrant’s Sutro Biopharma STRO Stock Holding History

First Quadrant’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-610	Closed	-$91K	–	475
2021 Q4	$91K	Buy	610 +10	+2%	+$1.79K	0.01%	378
2021 Q3	$113K	Hold	600	–	–	0.01%	379
2021 Q2	$112K	Hold	600	–	–	0.01%	379
2021 Q1	$137K	Sell	600 -99	-14%	-$23.5K	0.01%	397
2020 Q4	$152K	Buy	699 +99	+17%	+$16.4K	0.02%	388
2020 Q3	$60K	Sell	600 -940	-61%	-$88.8K	0.01%	477
2020 Q2	$120K	Buy	+1,540	New	+$148K	0.02%	509

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

First Quadrant's STRO Position: Q1 2022 in Review

First Quadrant sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 610 shares — an estimated $91K sold.

First Quadrant first reported a position in STRO in Q2 2020 and held it in 7 quarters. The position peaked at $152K in Q4 2020. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

First Quadrant reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 610 Sutro Biopharma shares in Q1 2022, an estimated $91K.
First Quadrant first reported a position in Sutro Biopharma in Q2 2020 and held it in 7 quarters.
First Quadrant's Sutro Biopharma position peaked at $152K in Q4 2020.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.